Previous Article | Next Article ![]()
Journal of Bacteriology, May 2003, p. 3139-3146, Vol. 185, No. 10
0021-9193/03/$08.00+0 DOI: 10.1128/JB.185.10.3139-3146.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Antoine Danchin,1 and Annie Kolb3
Unité de Génétique des Génomes Bactériens,1 Génopole-Plateau Protéomique,2 Laboratoire des Régulations Transcriptionnelles, Institut Pasteur, 75724 Paris Cedex 15, France3
Received 17 December 2002/ Accepted 3 March 2003
|
|
|---|
|
|
|---|
In the present work, the two-dimensional protein pattern of a CAP-deficient strain revealed an alteration in the level of ArgG, the arginosuccinate synthase involved in the arginine biosynthetic pathway. The study of the DNA promoter region of this gene showed the presence of the divergent promoter of metY, which encodes one of the two methionine tRNAs required for the initiation of protein synthesis. Since argG is known to be regulated by a specific repressor, ArgR, we studied the direct effect of CAP and ArgR, in vivo and in vitro, on the transcription of argG and metY. Finally, we demonstrated the coupling between the arginine biosynthetic pathway and a gene responsible for the initiation of protein synthesis.
|
|
|---|
2::cat mutation carried by strain IBPC 6411 (transduced from strain TK2 [21] and kindly provided by M. Springer) was introduced into MG1655 by transduction, giving rise to strain BE1623. Plasmid pDIA530 was constructed as follows: the fragment containing positions -417 to +90 of the argG promoter according to reference 9 was PCR amplified from genomic DNA using the Expand high-fidelity PCR system (Roche) and synthetic oligonucleotides 5'-CAGAAGGATCCTTTCAAATCCC-3', containing a BamHI site, and 5'-GGAGAAGCTTGAGAATCGTCGTC-3', containing a HindIII site. After purification, the fragment was cloned into the BamHI and HindIII restriction sites of PKK232-8 (Pharmacia). Plasmid pDIA560 was similar to pDIA530 except that the CAP binding site was mutated by PCR amplification with the synthetic oligonucleotide 5'AATCTGCAGGCATTATAGTAATCCACGCTCGATTTTGTCAACGTTTATTGC-3'. Plasmid pDIA539 contained the 268-bp argG promoter (see below), cloned into the HincII blunted site of pJCD01 (24). Strains were grown at 37°C in M9 minimal medium (26) supplemented with mannose (0.4%), thiamine (5 mg/ml), a mixture of all amino acids with or without arginine (0.005% of each), and when necessary 100 µg of ampicillin/ml. All experiments were performed in accordance with the European regulation requirements concerning the contained use of genetically modified organisms of group I (agreement no. 2735). |
View this table: [in a new window] |
TABLE 1. E. coli strains and plasmids used in this study
|
Quantitative analysis of mRNA. RNA was prepared, subjected to a slot blot, and quantified as previously described (36). The experiment was performed using two independent cultures with a probe corresponding to a 700-bp fragment of argG, generated by PCR amplification using the PCR DIG probe synthesis kit (Roche). Quantitation was made with the Bio-Rad Multi-Analyst system.
Gel mobility shift DNA binding assay.
A 268-bp fragment corresponding to the promoter region of argG (-212 to +56) according to reference 9 was amplified from genomic DNA by PCR using Pfu DNA polymerase (Stratagene) and synthetic oligonucleotides 5'-GTGTACCGAGACGGGACG-3' and 5'-TTAACTGATGATGAGCCTGG-3' (one of which was labeled with [
-32P]ATP by use of T4 polynucleotide kinase). The PCR product was purified with the High pure PCR product purification kit (Roche). Wild-type and mutated H159L CAP proteins were purified according to the method of Ghosaini et al. (13). Gel retardation experiments were performed as previously described (10), with some modifications: cAMP-CAP was bound to the labeled DNA fragment (0.2 nM) in a HEPES-Mg-K glutamate reaction buffer (40 mM HEPES [pH 8], 10 mM MgCl2, 100 mM K-glutamate) in the presence of 160 µM cAMP, at room temperature for 20 min.
DNase I footprinting experiments. The binding of cAMP-CAP and/or ArgR (kindly provided by D. Charlier) to the 268-bp DNA fragment encompassing the argG promoter was performed in HEPES-Mg-K glutamate buffer in the presence of 160 µM cAMP as previously described (10). After 20 min at room temperature, DNase I was added at a final concentration of 0.1 µg/ml. Reaction mixtures without any regulator were incubated at 37°C for 15 s and those containing CAP or/and ArgR were incubated at 37°C for 25 s. Reactions were stopped and were subjected to electrophoresis after heating at 90°C. Protected bands were identified by comparison with the same fragment treated for A+G sequencing reactions (25).
Chloramphenicol acetyltransferase assay. Bacteria carrying pDIA530 or pDIA560 were grown to log phase. Three 1.5-ml samples from two independent cultures were centrifuged for 5 min at 13,000 x g. Pellets were resuspended in 500 µl of 100 mM Tris-HCl (pH 7.8) and treated as described previously (35, 36).
In vitro transcription assays.
In vitro transcription experiments were performed at least two times with pDIA539 (1.2 nM) in buffer containing 40 mM Tris-HCl (pH 8), 10 mM MgCl2, 100 mM KCl, 0.5-mg/ml bovine serum albumin, 160 µM cAMP, and 1.4 mM dithiothreitol. After 20 min at room temperature, 14 µl of the mixture containing CAP or H159L CAP and/or ArgR at different concentrations was incubated at 30°C for 3 min. Then, 3.5 µl of a mixture containing nucleoside triphosphates, [
-32P]UTP, and RNA polymerase (15 nM) was added to perform polymerization at 30°C for 10 min. The reaction was stopped by adding 1% sodium dodecyl sulfate and xylene blue formamide. After heating at 70°C and electrophoresis gel, the data were quantified with a PhosphorImager (Molecular Dynamics).
ß-galactosidase assay. Overnight cultures were freshly diluted to an OD600 of 0.1 and were incubated 30 and 60 min at 30°C in M63 medium (26) supplemented with isopropyl-ß-D-thiogalactopyranoside (IPTG) (1 mM) and glycerol (0.4%) ± arginine (10 mM). ß-galactosidase activity was then determined by the method of Miller (27). Each assay was performed with two independent cultures.
|
|
|---|
![]() View larger version (68K): [in a new window] |
FIG. 1. (A) 2D gels of the wild-type strain (MG1655) and the crp mutant strain (BE1815) grown in minimal medium with or without 0.3 mM arginine. (B) Relative amounts of the ArgG protein in the four conditions.
|
![]() View larger version (20K): [in a new window] |
FIG. 2. The amount of argG mRNA in the wild-type and crp mutant strains was analyzed by slot blot hybridization with a specific 700-bp probe. Cultures were grown in minimal medium without arginine.
|
![]() View larger version (28K): [in a new window] |
FIG. 3. Competitive gel retardation assay with CAP and the argG promoter region (positions -212 and +56 with respect to the transcriptional start site). DNA fragments were incubated with the indicated concentrations of CAP.
|
, a protein of unknown function, the transcription-translation coupling factor NusA, and the translation initiation factor IF2. This suggests that the binding of the cAMP-CAP complex at a position centered on -19.5 upstream of the metY transcription start site may repress the transcription of the metY-nusA-infB operon from the P- promoter.
![]() View larger version (131K): [in a new window] |
FIG. 4. Analysis of CAP- and ArgR-binding sites in the argG and metY promoter region by DNase I footprinting assays. The labeled DNA fragment represents the coding strand of argG with cAMP-CAP complex alone (A), with 5 nM ArgR alone (+) (numbers correspond to ARG boxes) (B), with 100 nM CAP (+) and then with ArgR (C), and with 20 nM ArgR (+) and then with CAP (D). Protected regions are marked by solid lines. The coordinates were determined with G+A and correspond to the numbering used in Fig. 5. -, no protein was present.
|
![]() View larger version (25K): [in a new window] |
FIG. 5. Regulatory region of argG and metY. The nucleotide sequence corresponds to the fragment used in in vitro experiments. cAMP-CAP and ArgR-binding sites are indicated by boxes. The transcriptional start sites (+1) of argG and metY (promoter P-1) are indicated by arrows. The -10 and -35 boxes are indicated in bold.
|
![]() View larger version (34K): [in a new window] |
FIG. 6. Effect of a crp mutation (BE1815) on argG-cat transcriptional fusion activity. pDIA530 carries the intact promoter, whereas pDIA560 carries a promoter with an altered CAP site.
|
Binding of ArgR to the argG promoter region in the presence and absence of CAP. DNase I footprint experiments were first performed with ArgR (5 nM) at the argG promoter region (0.6 nM) and various arginine concentrations. It has been suggested that the degree of repression mainly depends on the concentration of arginine (14). No binding to the DNA fragment was observed in the absence of arginine, even at a high ArgR concentration (100 nM) (Fig. 4B). In the presence of 0.05 mM arginine, ArgR (7.5 nM) bound to the tandem ARG boxes around the argG +1 start site, whereas with 0.5 mM arginine, ArgR also bound to the third single ARG box (Fig. 4B). In the presence of 5 mM arginine and at a higher ArgR concentration (30 nM), a protected region was observed between the tandem ARG boxes and the single ARG box (positions 110 to 132) (data not shown; also Fig. 4C and D). This is thought to form a DNA loop, resulting from the binding to the three ARG boxes (9). DNase I footprint experiments were then performed with various concentrations of both regulators and in the presence and absence of 5 mM arginine (Fig. 4C and 4D). Again, in the absence of arginine, the ArgR regulator did not bind and had no effect on the binding of the cAMP-CAP complex to the operator. In the presence of arginine, ArgR bound to the three boxes, even at a high concentration of CAP (100 nM) (Fig. 4C and 4D). In contrast, the order with which the two regulators were added affected CAP binding. Indeed, the cAMP-CAP complex remained stably bound to DNA when ArgR was subsequently added in the presence of arginine (Fig. 4C). In contrast, when ArgR with arginine was already bound to DNA, the binding of CAP to DNA was less efficient, even at a high concentration (100 nM). However, its binding site was partially protected (Fig. 4D). Moreover, the hypersensitive bands observed between the CAP-binding site and the third ARG box with CAP alone were no longer visible in the presence of ArgR and arginine. These results suggest that the binding of each of the two regulators interferes with the binding of the other and that ArgR binding overrides CAP binding.
The cAMP-CAP complex activates argG and represses metY, whereas ArgR also represses metY but only in the presence of CAP.
In the different conditions of regulator binding, we performed in vitro transcription assays on plasmid pDIA539, which contained the metY-argG promoter region used in DNase I footprint experiments (Fig. 5). Again, a range of regulator concentrations as well as of the cofactor arginine was used. The effect of a mutated CAP protein carrying an H159L amino acid substitution in activating region I, which prevents interactions with the C-terminal domain of the
subunit of RNA polymerase (12), was also investigated. At 250 nM, CAP increased argG transcription twofold, whereas it decreased metY transcription 16-fold. The mutated protein had the same effect, although the inhibition of metY was at a slightly lower level (10-fold) (Fig. 7). This further supports the hypothesis that the binding of RNA polymerase to the metY promoter P-1 is inhibited in the presence of the cAMP-CAP complex. These results also suggest that the cAMP-CAP complex does not interact directly with RNA polymerase bound to the argG promoter: CAP could only act on DNA conformation, hence facilitating the binding of RNA polymerase to the -10 and -35 boxes of the promoter. In the absence of its corepressor arginine, the ArgR regulator had no effect on the transcription of either metY or argG, whether in the presence or in the absence of CAP (Fig. 7), in agreement with the DNase I footprinting results. With 0.05 mM arginine, when bound to the tandem ARG boxes, ArgR (9 nM) repressed argG transcription 10-fold (Fig. 7). In the presence of CAP, the inhibitory effect of ArgR plus arginine remained predominant and of the same magnitude as that on argG (Fig. 7). This result is consistent with the difference in the levels of ArgG protein measured in two-dimensional gel experiments (Fig. 1). At a higher arginine concentration (0.5 mM), when ArgR also bound to the third isolated ARG box, no further inhibition was observed at the argG promoter. In contrast, ArgR repressed the transcription of metY twofold in the presence of CAP, although ArgR had no detectable effect without CAP. This suggests that both regulators can bind to their own sites together in vitro, as shown by footprinting experiments, and that the binding of ArgR to the third ARG box, which occurs at a high concentration of arginine, reinforces the repressor effect of CAP on the binding of RNA polymerase to the metY P-1 promoter.
![]() View larger version (47K): [in a new window] |
FIG. 7. In vitro transcription assay by RNA polymerase from metY P-1 and argG promoters. pDIA539 was incubated with RNA polymerase in the presence or the absence (-) of regulators. Asterisks correspond to the H159L mutated CAP protein. Different transcripts are indicated by arrows.
|
.
Regulation of metY by cAMP-CAP complex and ArgR in vivo.
It was previously shown that the level of ß-galactosidase in the presence of IPTG reflects the efficiency of translation from the AUG start codon at the initiation step, independently of transcription, and thus the amount of
available (21). For a metZ mutant strain, in which
is synthesized only by metY, the level of ß-galactosidase translation is similar to that measured for a wild-type strain grown in minimal medium with glucose and Casamino Acids in the presence of IPTG (21). With these carbon sources, the level of cAMP is low. In contrast, in the presence of glycerol, the cAMP level is 10-fold higher (18). Therefore, the activity of ß-galactosidase was measured in cells that had been freshly diluted in minimal medium supplemented with 0.4% glycerol and with and without 10 mM arginine. After 30 and 60 min with glycerol alone, the ß-galactosidase level for the metZ strain BE1723 was 70% of that obtained for the wild type (Table 2). This further supports the repressive effect of the cAMP-CAP complex observed in vitro, although the effect was less marked in vivo. This could be explained by the presence of a second metY promoter, P0, downstream of P-1 (17). Surprisingly, with glycerol and arginine, no difference was observed between wild-type and metZ strains (Table 2), suggesting that CAP had no more effect on the metY level. In this assay, a high arginine concentration (10 mM) was used to allow ArgR to bind to the third ARG box. The result obtained suggests that the binding of ArgR to the third single ARG box in the chromosome prevents the binding of the cAMP-CAP complex in vivo.
|
View this table: [in a new window] |
TABLE 2. ß-Galactosidase activitya
|
|
|
|---|
In our study, we showed that argG is also regulated at a transcriptional level by the cAMP-CAP complex. This complex binds at position -166.5, with respect to the +1 start site, to the tatAGTGAtccacgCCACAttt sequence, which is very close to the consensus binding site 5'aaaTGTGAtntanaTCACAttt3' (7). At such a distant location, CAP would have no effect on transcription. However, we demonstrated that its binding resulted in a twofold increase in argG transcription. A CAP protein that had mutated in its activating region I (H159L), such that it was unable to interact with the C-terminal domain of the
subunit of RNA polymerase (12), had the same activating effect. This suggests that in the present case, the cAMP-CAP complex does not interact directly with RNA polymerase but only facilitates its binding to -10 and -35 boxes by the stabilization of the bending of this promoter region, making it more accessible for transcription initiation. The generation of a DNA loop upon ArgR binding supports the hypothesis that the region is particularly formed (9, 14). The binding of ArgR to the tandem ARG boxes around the +1 start site, in the presence of arginine (0.05 mM), repressed the transcription of argG 10-fold, even in the presence of the cAMP-CAP complex. Thus, a gene-specific regulation, i.e., mediated by ArgR, is here clearly predominant, as observed in the case of numerous targets of CAP (e.g., lac or mal). As a consequence, the cAMP-CAP complex may increase the rate of arginine synthesis under arginine starvation conditions. The argG gene should therefore be added to the list of genes induced by CAP and involved in the biosynthesis of amino acids such as isoleucine and valine, which are derived from glutamate (7). On the other hand, CAP is known to repress gadA, coding for a glutamate decarboxylase that participates in acid resistance and synthesizes GABA from glutamate (8). This suggests that CAP may favor the consumption of glutamate for amino acid biosynthesis instead of its use in other metabolic processes.
It is interesting that from the same position, the cAMP-CAP complex is both an activator of argG and a strong repressor of the metY-yhbC-nusA-infB operon, since its binding site overlaps the sequence between the -10 and -35 boxes of the P-1 promoter of the latter (15), which encodes
, the unknown protein YhbC, NusA, and the translation initiation factor IF2, respectively. However, an internal promoter, P2 (which directs the transcription of the protein coding part), and two intercistronic terminators, t1 and t2, are present downstream of metY. At 37°C, only a metY transcript is mainly observed, whereas under cold shock, distal genes are expressed through a transcription antitermination mechanism that is mediated by cold shock-induced Csp proteins, such as CspA (3, 32).
Two isoacceptor species of
are present in E. coli K-12:
coded by a three-tandem-repeated gene metZ (20), which represents the major fraction of the initiator tRNA pool, and
coded by metY, which represents the minor fraction (16). However, start codons AUG and GUG are recognized by both initiator tRNAs, and a metZ mutant strain is able to grow, although at a slower rate than the wild type or a metY-deficient strain (19, 21). The transcription of metZ is sensitive to ppGpp, the chemical mediator of stringent control, whereas this is not the case for metY (30). Before the present work, no regulation of the transcription of metY from its two promoters, P-1 and P0 (15, 17), had been described, although the relative fraction of
in the tRNA pool seemed to be dependent on the growth rate and on the Fis activator (31, 38). In this article, we show that a regulation mechanism for metY transcription exists, mediated by the cAMP-CAP complex and by the repressor of argG, ArgR. In fact, the cAMP-CAP complex repressed the transcription of metY from its promoter P-1 16-fold in vitro, and a significant inhibitory effect was also observed in vivo. By binding to the -10 and -35 boxes of the promoter, the cAMP-CAP complex blocked the access of RNA polymerase to promoter elements, as described for osmY (22) and cya P2 (1, 28), a mechanism that is very rarely used by CAP. ArgR only exerted its effect in the presence of CAP and a high concentration of arginine, i.e., when the third ARG box, which is centered at position -60 with respect to the +1 position of metY, was occupied by ArgR. However, the effects observed in vitro and in vivo seemed to contradict each other: ArgR repressed metY in vitro by increasing the cAMP-CAP complex repression effect, whereas in vivo it seemed to prevent the inhibitory action of CAP. It should be noted that the distance between the CAP binding site and the distal ArgR box is 42 bp, i.e., exactly four full turns of the DNA double helix, assuming a DNA pitch of 10.5 bp. This may mean that CAP and ArgR are located on the same side of the DNA helix, especially when the concentration of CAP is high, thus allowing them to act synergistically to repress the metY promoter in vitro. However, in footprinting experiments, ArgR with arginine, when bound first, partially prevented the binding of CAP, especially when CAP was added at the same concentration as ArgR. The intracellular concentration of cAMP is known to remain relatively low, even when cells are grown on glycerol, and in contrast to ArgR, the cAMP-CAP complex is a pleiotropic regulator that possesses many more available targets on the chromosome than the specific regulator ArgR. This suggests that more molecules of ArgR than of CAP are available to bind to the metY promoter. This could explain why ArgR prevents CAP binding in vivo.
Finally, our results confirm the hypothesis that the different promoters of Met-tRNA initiators respond to different signals under changing physiological conditions (15). Indeed, we showed that the synthesis of one of the two tRNA initiators is coregulated with one of the arginine biosynthetic genes, argG, by both the cAMP-CAP complex and the ArgR-specific repressor of arginine biosynthesis. The function of these gene products indicates that they are coupled through their direct involvement in protein biosynthesis. However, the direct relationship between arginine and one of the two methionine tRNA initiators remains unexplained, although it was recently found that methionine seems to act on the level of RNA messenger of genes involved in arginine biosynthesis for Bacillus subtilis (34). This further supports the existence of a strong link between methionine and arginine biosynthesis, namely polyamine biosynthesis, for the synthesis of spermidine.
Financial support came from the Institut Pasteur and the Centre National de la Recherche Scientifique (URA 1129 and URA 2171 and FRE2364).
Present address: Laboratoire de Dynamique, Evolution et Expression de Génomes de Microorganismes, FRE 2326 ULP/CNRS, 67083 Strasbourg Cedex, France. ![]()
|
|
|---|
s-dependent stationary-phase-induced and osmotically regulated osmY (csi-5) gene suggests novel roles for Lrp, cyclic AMP (cAMP) receptor protein-cAMP complex, and integration host factor in the stationary-phase response of Escherichia coli. J. Bacteriol. 175:7910-7917.
s and requires activation by cAMP-CRP. J. Mol. Biol. 276:339-353.[CrossRef][Medline]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»